98%
921
2 minutes
20
Aims: Radiotherapy is an essential component of cancer treatment, requiring accurate dose planning to optimise tumour control while sparing healthy tissues. This study, originating from a radiobiology workshop held during the 27th Congrès National de Cancérologie et de Radiothérapie-2024 in Sousse, Tunisia, aims to investigate advanced dose modelling approaches, focussing on the linear-quadratic (LQ) and linear-quadratic-linear (LQL) models, to refine the calculation of biologically effective doses (BED) and improve treatment personalisation.
Methods: The workshop brought together experts in the field to discuss and evaluate the latest advancements in dose modelling, providing a comprehensive overview of current best practices and emerging trends. Using tools such as LQL-equiv and other BED calculators, we integrated patient-specific data (eg, fractionation schedules and organ-at-risk (OAR) constraints) to predict outcomes such as normal tissue complication probabilities (NTCPs). Unlike many theoretical studies, our approach embeds these models within a unified interface tailored to real clinical scenarios, enabling practitioners to simulate and adjust treatment plans based on complex, practical constraints.
Results: Through a series of clinical case studies (including treatment interruptions, palliative boosts, and re-irradiation scenarios), participant responses were analysed using the Jaccard similarity index, revealing a significant lack of consensus in treatment planning decisions (mean agreement of 25.83%). This variation illustrates the current ambiguity among clinicians regarding which model to use and how to apply it, despite access to advanced tools. This heterogeneity in decision-making could lead to divergent treatment recommendations for patients with clinically similar profiles.
Conclusion: While the LQ and LQL models offer promising tools for personalised radiotherapy, their interpretation and implementation remain highly variable. In addition, the question of professional responsibility in dose equivalence calculations emerged as a key issue as many departments lack clearly defined accountability frameworks. This study emphasises the need for standardised guidelines, enhanced training programs, and decision support systems to reduce interobserver variability and ensure effective clinical adoption, ultimately improving patient care. The findings underscore the importance of harmonising predictive modelling practices to achieve more consistent and effective radiotherapy outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clon.2025.103893 | DOI Listing |
Clin Oncol (R Coll Radiol)
September 2025
Centre Médical IBN Khaldoun, Radiotherapy Unit, Hammam Sousse, 4011, Republic of Tunisia.
Aims: Radiotherapy is an essential component of cancer treatment, requiring accurate dose planning to optimise tumour control while sparing healthy tissues. This study, originating from a radiobiology workshop held during the 27th Congrès National de Cancérologie et de Radiothérapie-2024 in Sousse, Tunisia, aims to investigate advanced dose modelling approaches, focussing on the linear-quadratic (LQ) and linear-quadratic-linear (LQL) models, to refine the calculation of biologically effective doses (BED) and improve treatment personalisation.
Methods: The workshop brought together experts in the field to discuss and evaluate the latest advancements in dose modelling, providing a comprehensive overview of current best practices and emerging trends.
Cancers (Basel)
April 2025
Group of Medical Physics and Biomathematics, Instituto de Investigación Sanitaria de Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Background/objectives: Clinical studies have shown a marked reduction in tumor control in prostate cancer treated with radically hypofractionated high-dose-rate brachytherapy (HDR-BT). The purpose of this study was to analyze the dose-response of prostate cancer treated with HDR-BT, specifically aiming at investigating the potential failure of the linear-quadratic (LQ) model to describe the response at large doses-per-fraction.
Methods: We collated a dataset of dose-response to HDR-BT (3239 patients).
Int J Radiat Oncol Biol Phys
June 2025
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Purpose: To develop and compare normal tissue complication probability (NTCP) models for recurrent brain metastases (BMs) treated with repeat single-fraction stereotactic radiosurgery (SRS), considering time-dependent discounted prior dose.
Methods And Materials: We developed three NTCP models (M0, M1-retreat, and M1-combo models) of BMs treated with GammaKnife-based SRS. The maximum dose is 0.
Radiother Oncol
January 2024
Department of Radiation Oncology, CyberKnife Center, and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin, China. Electronic address: zyuan@tmu
Phys Med Biol
December 2023
Department of Radiation Oncology, Medical College of Wisconsin, WI 53226, United States of America.
Different radiation therapy (RT) strategies, e.g. conventional fractionation RT (CFRT), hypofractionation RT (HFRT), stereotactic body RT (SBRT), adaptive RT, and re-irradiation are often used to treat head and neck (HN) cancers.
View Article and Find Full Text PDF